Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The improvement of conventional imaging techniques has led to an increased detection rate of
different adrenal tumors. Since those tumors can belong to a variety of entities the
therapeutic consequences also show considerable variation. In order to definitely determine
the type of tumor, invasive procedures like CT guided biopsies are often required, which
could be avoided by a tumor specific imaging method. The presently available scintigraphic
procedures are either time consuming and lead to high radiation exposure or are technically
demanding. The steroidogenic enzymes CYP11B1 (11ß-hydroxylase)and CYP11B2 (aldosterone
synthase)are expressed exclusively in the adrenal cortex and therefore represent suitable
targets for a specific imaging technique. In our project we evaluate 123I-Iodometomidate
which binds to both CYP11B enzymes as radiotracer for adrenal scintigraphy.